We are a research-based development stage pharmaceutical company that discovers and develops innovative medicines. We leverage Innovate's proprietary supra-molecular chemistry platform in the discovery and design of novel treatments in areas of unmet need
IP1867B opens up the long held hope that combinations of targeted agents can be used to precisely attack the specific drivers of cancers. This form of personalised medicine allows us to offer not only a wide range of targeted drugs with low toxicity, but at a cost that makes such combinations feasible.
Manufacturing is quality assured.